Cubist Systematic Strategies, LLC Caribou Biosciences, Inc. Transaction History

Cubist Systematic Strategies, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.82 - $8.26 $267,775 - $458,884	55,555 Added 2642.96%	57,657 $296,000
Q4 2023 Feb 14, 2024	BUY	$3.58 - $6.25 $7,525 - $13,137	2,102 New	2,102 $12,000
Q4 2022 Feb 14, 2023	SELL	$5.57 - $11.01 $8,355 - $16,515	-1,500 Reduced 85.86%	247 $1,000
Q2 2022 Aug 15, 2022	SELL	$5.1 - $9.74 $539,437 - $1.03 Million	-105,772 Reduced 98.38%	1,747 $9,000
Q1 2022 May 16, 2022	BUY	$8.42 - $15.32 $896,047 - $1.63 Million	106,419 Added 9674.45%	107,519 $987,000
Q4 2021 Feb 14, 2022	SELL	$14.59 - $23.26 $135,643 - $216,248	-9,297 Reduced 89.42%	1,100 $17,000
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $163,752 - $314,925	10,397 New	10,397 $248,000

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $114M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.